Advisory Council on the Misuse of Drugs. (2020) An assessment of the harms of gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and closely related compounds. London: Advisory Council on the Misuse of Drugs.
| Preview | Title | Contact |
|---|---|---|
|
PDF (An assessment of the harms of gamma-hydroxybutyric acid)
- Published Version
1MB |
This report reviews the evidence of harms of GHB and related compounds that have emerged since the UK ACMD’s last significant assessment of the risks of GHB and its prodrugs, GBL and 1,4-butanediol (1,4-BD) in [ACMD, 2008a]. The aim is to enable the ACMD to assess the level of harms associated with these compounds and to make recommendations to mitigate these harms – including (but not limited to) recommendations on the most appropriate classification and scheduling of these compounds under the MDA and MDR respectively.
B Substances > New (novel) psychoactive substances > Other novel substances > GHB / GBL (Gamma hydroxybutyric / Gamma butyrolactone)
L Social psychology and related concepts > Legal availability or accessibility
MM-MO Crime and law > Substance use laws > Drug laws
VA Geographic area > Europe > United Kingdom
Repository Staff Only: item control page